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Abstract
Economic evaluations of health interventions pose a particular challenge
for reporting. There is also a need to consolidate and update existing
guidelines and promote their use in a user friendly manner. The
Consolidated Health Economic Evaluation Reporting Standards
(CHEERS) statement is an attempt to consolidate and update previous
health economic evaluation guidelines efforts into one current, useful
reporting guidance. The primary audiences for the CHEERS statement
are researchers reporting economic evaluations and the editors and
peer reviewers assessing them for publication.
The need for new reporting guidance was identified by a survey of
medical editors. A list of possible items based on a systematic review
was created. A two round, modified Delphi panel consisting of
representatives from academia, clinical practice, industry, government,
and the editorial community was conducted. Out of 44 candidate items,
24 items and accompanying recommendations were developed. The
recommendations are contained in a user friendly, 24 item checklist. A
copy of the statement, accompanying checklist, and this report can be
found on the ISPORHealth Economic Evaluations Publication Guidelines
Task Forcewebsite (www.ispor.org/TaskForces/EconomicPubGuidelines.
asp).
We hope CHEERS will lead to better reporting, and ultimately, better
health decisions. To facilitate dissemination and uptake, the CHEERS
statement is being co-published across 10 health economics andmedical
journals. We encourage other journals and groups, to endorse CHEERS.
The author team plans to review the checklist for an update in five years.
Health economic evaluations are conducted to inform resource
allocation decisions. Economic evaluation has been defined as
“the comparative analysis of alternative courses of action in
terms of both their costs and their consequences.”1All economic
evaluations assess costs, but approaches to measuring and
valuing the consequences of health interventions may differ
(see box).
Economic evaluations have beenwidely applied in health policy,
including the assessment of prevention programmes (such as
vaccination, screening, and health promotion), diagnostics,
treatment interventions (such as drugs and surgical procedures),
organisation of care, and rehabilitation. Economic evaluations
are increasingly being used for decision making and are an
important component of programmes for health technology
assessment internationally.2
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Forms of economic evaluation1
Specific forms of analysis reflect different approaches to evaluating the consequences of health interventions. Health consequences may
be estimated from a single analytical (experimental or non-experimental) study, a synthesis of studies, mathematical modelling, or a
combination of modelling and study information.
Cost consequences analysis examines costs and consequences without attempting to isolate a single consequence or aggregate
consequences into a single measure
Cost minimisation analysis (CMA)—The consequences of compared interventions are required to be equivalent, and only relative costs
are compared
Cost effectiveness analysis (CEA)measures consequences in natural units, such as life years gained, disability days avoided, or cases
detected. In a variant of CEA, often called cost utility analysis, consequences are measured in terms of preference-based measures of
health, such as quality adjusted life years or disability adjusted life years.
Cost benefit analysis—Consequences are valued in monetary units.
Readers should be aware that an economic evaluation might be referred to as a “cost effectiveness analysis” or “cost benefit analysis” even
if it does not strictly adhere to the definitions above. Multiple forms may also exist within a single evaluation. Different forms of analysis
provide unique advantages or disadvantages for decision making. The Consolidated Health Economic Evaluation Reporting Standards
(CHEERS) statement can be used with any form of economic evaluation.
Reporting challenges and shortcomings
in health economic evaluations
Compared with clinical studies, which report the consequences
of an intervention only, economic evaluations require more
reporting space for additional items, such as resource use, costs,
preference related information, and cost effectiveness results.
This creates challenges for editors, reviewers, and those who
wish to scrutinise a study’s findings.3 There is evidence that the
quality of reporting of economic evaluations varies widely and
could potentially benefit from improved quality assurance
mechanisms.4 5
With the increasing number of publications available, and
opportunity costs from decisions based on misleading study
findings, transparency and clarity in reporting are important. In
addition, outside of economic evaluations conducted alongside
clinical trials, there are no widespread mechanisms for
warehousing economic evaluation data to allow for independent
interrogation, such as ethics review proceedings, regulator
dossiers, or study registries. Instead, independent analysis may
rely on the record keeping of individual investigators.
Even if measures to promote transparency exist, such as
registries, biomedical journal editors have increasingly promoted
and endorsed the use of reporting guidelines. Endorsement of
guidelines by journals for randomised controlled trials has been
shown to improve reporting.6 The combination of the risk of
making costly decisions due to poor reporting with the lack of
mechanisms that promote accountability makes transparency
in reporting economic evaluations especially important and a
primary concern among journal editors and decision makers.3 7
Aim and scope
The aim of the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) statement is to provide
recommendations, in the form of a checklist, to optimise
reporting of health economic evaluations. The need for a
contemporary reporting guidance for economic evaluations was
recently identified by researchers and biomedical journal
editors.8 The CHEERS statement attempts to consolidate and
update previous efforts 9-20 into a single useful reporting
guidance.
The primary audiences for the CHEERS statement are
researchers reporting economic evaluations and the editors and
peer reviewers evaluating their publication potential. We hope
the statement (which consists of a 24 item checklist and
accompanying recommendations on the minimum amount of
information to be included when reporting economic
evaluations) is a useful and practical tool for these audiences
and will improve reporting and, in turn, health and healthcare
decisions. To best understand and apply the recommendations
contained within the statement, we encourage readers to access
the Explanation and Elaboration Report.21
Development of the CHEERS statement
The statement was developed by a task force supported by the
International Society for Pharmacoeconomics and Outcomes
Research (ISPOR), as part of a broader initiative to facilitate
and encourage the interchange of expert knowledge and develop
best practices. The CHEERS Task Force members were chosen
by the chair of the task force primarily based on their
longstanding academic expertise and contribution to the
multidisciplinary field of health economic evaluation. In addition
to four members of the task force with doctorates in economics
and its sub-discipline of health economics (AHB,MD, JM, SP),
members included experts in health technology assessment and
decision making (FA, AHB, DH, MD, JM) and in clinical
epidemiology and biostatistics (AHB, EL, DM), those in active
clinical practice (EL, FA), and those with previous experience
in reporting guideline development (MD, DM). All members
are researchers in applied health and health policy, with five
members currently serving as editors for journals in the field
(AHB, CC, MD, DG, EL).
The CHEERS Task Force followed current recommendations
for developing reporting guidelines.22 Briefly, the need for new
guidance was first identified through a survey of members of
the World Association of Medical Editors. Of the 6% (55/965)
who responded, 91% (n=50) indicated they would use a standard
if one were widely available.8 Next, published checklists or
guidance documents related to reporting economic evaluations
were identified from a systematic review and survey of task
force members.23 Both of these activities were used to create a
preliminary list of items to include when reporting economic
evaluations. Recommendations of the minimum set of reporting
items were then developed through a modified Delphi panel
process. Forty eight individuals identified by the task force with
broad geographical representation and representing academia,
biomedical journal editors, the pharmaceutical industry,
government decision makers, and those in clinical practice were
invited to participate. Thirty eight agreed to participate.
Participants were asked to score importance on a Likert scale
and the average scores, weighted by each individual’s confidence
in ability to score, were then used to rank items. A cut-off point
was applied to the ranked list to determine the minimum number
of items important for reporting.
The CHEERS statement recommendations have been
independently reviewed and subsequently revised by task force
members. The recommendations are entirely those of the task
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force—the sponsors of the study had no role in study design,
data analysis, data interpretation, or writing of the final
recommendations. Amore complete description of themethods
and findings of the Delphi panel are found in the larger
explanation and elaboration document.21
Checklist items
The final recommendations are subdivided into six main
categories: (1) title and abstract; (2) introduction; (3) methods;
(4) results; (5) discussion; and (6) other. The recommendations
are contained in a user friendly, 24 item checklist (table⇓) to
aid users who wish to follow them. A copy of the checklist can
also be found on the CHEERS Task Force website. (www.ispor.
org/TaskForces/EconomicPubGuidelines.asp). In order to
encourage dissemination and use of a single international
standard for reporting, the task force approached 14 journals
identified as either the largest publishers of economic
evaluations or widely read by the medical and research
community. Thirteen journals responded, and 10 expressed their
ability and interest in endorsing this guidance. The CHEERS
statement is being simultaneously published in BMCMedicine,
BMJ, BJOG: An International Journal of Obstetrics and
Gynaecology, Clinical Therapeutics, Cost Effectiveness and
Resource Allocation, The European Journal of Health
Economics, International Journal of Technology Assessment in
Health Care, Journal of Medical Economics,
Pharmacoeconomics, and Value in Health. To facilitate wider
dissemination and uptake of this reporting guidance, we
encourage other journals and groups to consider endorsing
CHEERS.
Concluding remarks
As the number of published health economic evaluations
continues to grow, we believe more transparent and complete
reporting of methods and findings will be increasingly important
to facilitate interpretation and comparison of studies. We hope
the CHEERS statement, consisting of recommendations in a 24
item checklist, will be viewed as an effective consolidation and
update of previous efforts and serve as a starting point for
standard reporting going forward.
We believe the CHEERS statement represents a considerable
expansion over previous efforts. The strength of our approach
is that it was developed in accordance with current
recommendations for the development of reporting guidelines,
using an international and multidisciplinary team of editors and
content experts in economic evaluation and reporting.22 Similar
to the approach taken with other widely accepted guidelines,
we have defined a minimum set of criteria though a modified
Delphi technique and have translated these into
recommendations, an explanatory document with explanations,
and a checklist. Unlike some previous reporting guidance for
economic evaluation, we have also made every effort to be
neutral about the conduct of economic evaluation, allowing
analysts the freedom to choose different methods.
There may be several limitations to our approach. A larger
Delphi panel with a different composition could have led to a
different final set of recommendations.24 Some less common
approaches and contexts (such as public health, developing
countries, and system dynamic models) for conducting health
economic evaluation may not be well represented by our sample
of experts. Additionally, like many Delphi panel processes, we
based decisions to reject or accept criteria on arbitrary levels of
importance. However, we feel the group recruited to create the
statement is sufficiently knowledgeable of the more common
applications of economic evaluation, and the rules used to select
criteria were created a priori and are consistent with previous
efforts.
We believe it will be important to evaluate the effects of
implementation of this statement and checklist on reporting in
future economic evaluations. As methods for the conduct of
economic evaluation continue to evolve, it will also be important
to revisit or extend the guidance. The CHEERS Task Force feels
that this statement should be reviewed for updating five years
from its release.
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Table
Table 1| CHEERS checklist—Items to include when reporting economic evaluations of health interventions
Reported on
page No/
line NoRecommendationItem NoSection/item
Title and abstract
Identify the study as an economic evaluation or use more specific terms such as “cost-effectiveness
analysis”, and describe the interventions compared.
1Title
Provide a structured summary of objectives, perspective, setting, methods (including study design
and inputs), results (including base case and uncertainty analyses), and conclusions.
2Abstract
Introduction
Provide an explicit statement of the broader context for the study.3Background and objectives
Present the study question and its relevance for health policy or practice decisions.
Methods
Describe characteristics of the base case population and subgroups analysed, including why they
were chosen.
4Target population and subgroups
State relevant aspects of the system(s) in which the decision(s) need(s) to be made.5Setting and location
Describe the perspective of the study and relate this to the costs being evaluated.6Study perspective
Describe the interventions or strategies being compared and state why they were chosen.7Comparators
State the time horizon(s) over which costs and consequences are being evaluated and say why
appropriate.
8Time horizon
Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.9Discount rate
Describe what outcomes were used as the measure(s) of benefit in the evaluation and their
relevance for the type of analysis performed.
10Choice of health outcomes
Single study-based estimates: Describe fully the design features of the single effectiveness study
and why the single study was a sufficient source of clinical effectiveness data.
11aMeasurement of effectiveness
Synthesis-based estimates: Describe fully the methods used for identification of included studies
and synthesis of clinical effectiveness data.
11b
If applicable, describe the population and methods used to elicit preferences for outcomes.12Measurement and valuation of
preference based outcomes
Single study-based economic evaluation: Describe approaches used to estimate resource use
associated with the alternative interventions. Describe primary or secondary research methods
for valuing each resource item in terms of its unit cost. Describe any adjustments made to
approximate to opportunity costs.
13aEstimating resources and costs
Model-based economic evaluation: Describe approaches and data sources used to estimate
resource use associated with model health states. Describe primary or secondary researchmethods
for valuing each resource item in terms of its unit cost. Describe any adjustments made to
approximate to opportunity costs.
13b
Report the dates of the estimated resource quantities and unit costs. Describe methods for adjusting
estimated unit costs to the year of reported costs if necessary. Describe methods for converting
costs into a common currency base and the exchange rate.
14Currency, price date, and
conversion
Describe and give reasons for the specific type of decision-analytical model used. Providing a
figure to show model structure is strongly recommended.
15Choice of model
Describe all structural or other assumptions underpinning the decision-analytical model.16Assumptions
Describe all analytical methods supporting the evaluation. This could include methods for dealing
with skewed, missing, or censored data; extrapolation methods; methods for pooling data;
approaches to validate or make adjustments (such as half cycle corrections) to a model; and
methods for handling population heterogeneity and uncertainty.
17Analytical methods
Results
Report the values, ranges, references, and, if used, probability distributions for all parameters.
Report reasons or sources for distributions used to represent uncertainty where appropriate.
Providing a table to show the input values is strongly recommended.
18Study parameters
For each intervention, report mean values for the main categories of estimated costs and outcomes
of interest, as well as mean differences between the comparator groups. If applicable, report
incremental cost-effectiveness ratios.
19Incremental costs and outcomes
Single study-based economic evaluation: Describe the effects of sampling uncertainty for the
estimated incremental cost and incremental effectiveness parameters, together with the impact
of methodological assumptions (such as discount rate, study perspective).
20aCharacterising uncertainty
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(continued)
Reported on
page No/
line NoRecommendationItem NoSection/item
Model-based economic evaluation: Describe the effects on the results of uncertainty for all input
parameters, and uncertainty related to the structure of the model and assumptions.
20b
If applicable, report differences in costs, outcomes, or cost-effectiveness that can be explained
by variations between subgroups of patients with different baseline characteristics or other observed
variability in effects that are not reducible by more information.
21Characterising heterogeneity
Discussion
Summarise key study findings and describe how they support the conclusions reached. Discuss
limitations and the generalisability of the findings and how the findings fit with current knowledge.
22Study findings, limitations,
generalisability, and current
knowledge
Other
Describe how the study was funded and the role of the funder in the identification, design, conduct,
and reporting of the analysis. Describe other non-monetary sources of support.
23Source of funding
Describe any potential for conflict of interest of study contributors in accordance with journal policy.
In the absence of a journal policy, we recommend authors comply with International Committee
of Medical Journal Editors recommendations.
24Conflicts of interest
For consistency, the CHEERS statement checklist format is based on the format of the CONSORT statement checklist
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